US FDA grants breakthrough therapy designation to Nuvalent's NVL─655 to treat locally advanced or metastatic ALK─...
Nuvalent Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation …